Neural effects of gut‐ and brain‐derived glucagon‐like peptide‐1 and its receptor agonist
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) is derived from both the enteroendocrine L cells and preproglucagon‐expressing neurons in the nucleus tractus solitarius (NTS) of the brain stem. As GLP‐1 is cleaved by dipeptidyl peptidase‐4 yielding a half‐life of less than 2 min, it is plausible that the gut‐derived GLP‐1, released postprandially, exerts its effects on the brain mainly by interacting with vagal afferent neurons located at the intestinal or hepatic portal area. GLP‐1 neurons in the NTS widely project in the central nervous system and act as a neurotransmitter. One of the physiological roles of brain‐derived GLP‐1 is restriction of feeding. GLP‐1 receptor agonists have recently been used to treat type 2 diabetic patients, and have been shown to exhibit pleiotropic effects beyond incretin action, which involve brain functions. GLP‐1 receptor agonist administered in the periphery is stable because of its resistance to dipeptidyl peptidase‐4, and is highly likely to act on the brain by passing through the blood–brain barrier (BBB), as well as interacting with vagal afferent nerves. Central actions of GLP‐1 have various roles including regulation of feeding, weight, glucose and lipid metabolism, cardiovascular functions, cognitive functions, and stress and emotional responses. In the present review, we focus on the source of GLP‐1 and the pathway by which peripheral GLP‐1 informs the brain, and then discuss recent findings on the central effects of GLP‐1 and GLP‐1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 2×
“These effects were diminished with simultaneous central infusion of the GLP1 receptor antagonist exendin(9-39), and abolished in GLP-1 receptor knockout mice.”
BackgroundAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 2×
“These effects were diminished with simultaneous central infusion of the GLP1 receptor antagonist exendin(9-39), and abolished in GLP-1 receptor knockout mice.”
BackgroundInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 2×
“These effects were diminished with simultaneous central infusion of the GLP1 receptor antagonist exendin(9-39), and abolished in GLP-1 receptor knockout mice.”
BackgroundRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 3×
“These effects were diminished with simultaneous central infusion of the GLP1 receptor antagonist exendin(9-39), and abolished in GLP-1 receptor knockout mice.”
BackgroundYamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Cited by
The role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357
Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity
Timper, K., & Brüning, J. C. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.026609 · Cited by 802
Short chain fatty acids: Microbial metabolites for gut-brain axis signalling
O'Riordan, K. J., Collins, M. K., Moloney, G. M., Knox, E. G., Aburto, M. R., Fülling, C., Morley, S. J., Clarke, G., Schellekens, H., & Cryan, J. F. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111572 · Cited by 713
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“These neurons project to the thalamus, hypothalamus and cortical regions, and induce the release of GLP-1 by various stimuli in a mechanism similar to L-cells of the small intestine (30, 31, 240, 243).”
BackgroundThe gut microbiota–brain axis in neurological disorder
Ullah, H., Arbab, S., Tian, Y., Liu, C.-Q., Chen, Y., Qijie, L., Khan, M. I. U., Hassan, I. U., & Li, K. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1225875 · Cited by 255
le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00356-x · Cited by 237
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218
“GLP-1 stimulates insulin secretion from the pancreatic beta-cells under hyperglycemic conditions and reduces glucagon secretion from the alfa-cells recovering insulin sensitivity and enhancing glycemic homeostasis (Meloni et al., 2013; Katsurada and Yada, 2016).”
BackgroundDiet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
Burmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · Diabetes · doi:10.2337/db16-1102 · Cited by 136
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03302-1 · Cited by 110
“GLP-1 is expressed in different parts of the brain and affects satiety centre, water intake, stress reaction, neurogenesis, neurodegeneration, thermogenesis, and energy homeostasis (6).”
BackgroundBazzari, F. H., Abdallah, D. M., & El-Abhar, H. S. (2019) · Molecules · doi:10.3390/molecules24101992 · Cited by 98
Detka, J., & Głombik, K. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00274-8 · Cited by 79
“As an insulinotropic hormone, GLP-1 plays a substantial role in the regulation of glucose homeostasis, not only in the periphery but also in the central nervous system [90].”
BackgroundFarkas, I., Vastagh, C., Farkas, E., Bálint, F., Skrapits, K., Hrabovszky, E., Fekete, C., & Liposits, Z. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00214 · Cited by 79
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
Dietary Regulation of Gut-Brain Axis in Alzheimer’s Disease: Importance of Microbiota Metabolites
Frausto, D. M., Forsyth, C. B., Keshavarzian, A., & Voigt, R. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.736814 · Cited by 61
Direct and indirect effects of lipids on microglia function
Leyrolle, Q., Layé, S., & Nadjar, A. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134348 · Cited by 50
Qin, W., Ying, W., Hamaker, B., & Zhang, G. (2021) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12808 · Cited by 48
Role of liraglutide in Alzheimer’s disease pathology
Vargas-Soria, M., Carranza-Naval, M. J., del Marco, A., & Garcia-Alloza, M. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00853-0 · Cited by 44
Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
Lee, S. E., Lee, N. Y., Kim, S. H., Kim, K.-A., & Kim, Y. S. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113830 · Cited by 27
Psilopanagioti, A., Nikou, S., Logotheti, S., Arbi, M., Chartoumpekis, D. V., & Papadaki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314899 · Cited by 22
“Nesfatin-1 neurons have been shown to contribute to 106 the anorexigenic effects of GLP-1 in an animal model of GLP-1R-mediated feeding 107 suppression [17, 18].”
Background
Metadata
- Authors
- Katsurada, K., & Yada, T.
- Venue
- Journal of Diabetes Investigation
- Publisher
- Wiley
- Published
- 2016-03-31
- Volume
- 7
- Issue
- S1
- Pages
- 64-69
- ISSN
- 2040-1116 (ISSN-L)
- 2040-1124
- OpenAlex
- W2334243568
- Cited by
- 119
- References
- 13
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.